Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
Chiesi Group agreed to acquire KalVista Pharmaceuticals (Nasdaq: KALV) for $27.00 per share in cash, implying an equity value of approximately $1.9bn. The tender-offer transaction, unanimously approved by both boards, is expected to close in Q3 2026 pending customary closing conditions and regulatory approvals. Chiesi will assume responsibility for EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema, which launched in the U.S. in July 2025 and reached $49M in 2025 sales. Chiesi says sebetralstat is expected to contribute to its 2030 €6bn revenue target.
Alpha Cognition (Nasdaq: ACOG) appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of finance, strategy, and operations experience, including CFO roles at Radius Health and 9 Meters, and Biogen P&L responsibility for >$1 billion across 30 countries. The company said her expertise will support the commercial launch of ZUNVEYL and ongoing development of its sublingual program. Alpha Cognition also announced that founding director Len Mertz will not seek re-election after guiding the company to an FDA-approved product.
KalVista Pharmaceuticals (Nasdaq: KALV) will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 10:15 a.m. EST in a fireside chat.
A live audio webcast will be available on the company’s Investor website, with an archived replay posted about two hours after the event.
KalVista Pharmaceuticals (Nasdaq: KALV) granted inducement stock options to five newly hired employees totaling 66,375 shares on April 1, 2026. Options exercise price will equal the first reported closing price after the grant date. One-fourth vests after one year; remaining vest monthly over three years. Each option has a 10-year term and is governed by the company’s Inducement Equity Incentive Plan and individual option agreements, and the grants comply with Nasdaq Listing Rule 5635(c)(4).
KalVista (Nasdaq: KALV) reported positive interim Phase 3 KONFIDENT-KID results for EKTERLY (sebetralstat) in children aged 2-11.
Among 172 treated HAE attacks in 33 pediatric participants (data cut Dec 15, 2025): mean 0.7 attacks treated/patient/month, median time to treatment 25 minutes (67% within 1 hour), 88.9% mild/moderate. In the 150 mg cohort median symptom relief was 1.5 hours and complete resolution 12 hours. Sebetralstat was well tolerated with no serious or treatment-related adverse events and no swallowing issues. Enrollment finished one year early; KalVista expects a US NDA in Q3 2026 and a 2027 launch if approved.
KalVista Pharmaceuticals (Nasdaq: KALV) reported results for the eight months ended December 31, 2025, following a fiscal-year change. EKTERLY generated $49.1 million global net product revenue since launch and recorded 1,702 US patient start forms through February 28, 2026 (about 20% of the US patient population).
Key clinical progress includes completed pediatric Phase 3 enrollment and planned US NDA filing in Q3 2026; cash and marketable securities were approximately $300.2 million at year-end.
KalVista Pharmaceuticals (Nasdaq: KALV) will present five abstracts, including a late-breaking oral poster, at the 2026 Global Angioedema Leadership Conference in Madrid from March 26–29, 2026.
The late-breaking oral is an interim analysis of KONFIDENT-KID evaluating sebetralstat for on-demand treatment of hereditary angioedema attacks in children aged 2–11, plus four KONFIDENT-S and patient-survey posters.
KalVista Pharmaceuticals (Nasdaq: KALV) will host a conference call and webcast on March 25, 2026 at 8:30 a.m. ET to review eight months fiscal year 2025 financial results and provide a corporate update. The live webcast and an archived replay will be available on the company investor website.
KalVista Pharmaceuticals (NASDAQ: KALV) reported inducement option grants for a newly hired employee: an aggregate of 6,750 options granted on March 1, 2026, under Nasdaq Listing Rule 5635(c)(4). Exercise price will equal the first reported closing price after the grant. Options vest 25% after one year, then monthly over three years, have a 10-year term, and are governed by the company's Inducement Equity Incentive Plan and a stock option agreement.
KalVista (Nasdaq: KALV) reported new clinical data showing high patient satisfaction and shifting treatment behavior with oral EKTERLY (sebetralstat). In KONFIDENT-S, patients treated 2,464 attacks with sebetralstat; 83.1% of treated attacks rated satisfied or better and use of injectables fell with repeated use.
Analyses showed treating within 30 minutes predicted faster symptom relief, with simulations suggesting nearly 90% might experience relief within 12 hours.